TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled to undergo total joint arthroplasty at area hospital~* Primary unilateral total hip or knee arthroplasty scheduled within approximately 6 months of the initial evaluation clinic visit~Exclusion Criteria:~* Patients scheduled to undergo a revision or bilateral procedure~* Receiving chronic opioid therapy, defined as the use of opioids on most days for \> 3 month~* Allergy to opioids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- CYP2D6-guided opioid therapy (Type: ACTIVE_COMPARATOR): Participants randomized to the CYP2D6-guided arm will have their CYP2D6 genotyping completed prior to surgery (in the absence of any genotyping error) with results reported in the electronic health record (EHR). Patients will be categorized as CYP2D6 PM, IM, NM, or UM based on CYP2D6 genotype/activity score and FDA guidance on drug interactions. Strong inhibitors (e.g. bupropion, fluoxetine, paroxetine) phenoconvert patients to PMs, with moderate inhibitors (e.g. duloxetine, fluvoxamine) reducing CYP2D6 activity scores by 50%.
- Usual Care (Type: NO_INTERVENTION): Participants randomized to the usual care arm will have their DNA collected at the start of the study and stored at the lab until after they have completed their surgery and the 2-week follow-up, at which time, their sample was genotyped with the results reported in the EHR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes mellitus (T2DM)~* Have HbA1c between ≥7.0% and ≤10.5%~* Be on stable treatment with unchanged dose of metformin \>1500 mg/day for at least 3 months prior to screening~* Be of stable weight (±5%) for at least 3 months before screening~* Have a body mass index (BMI) ≥25 kilograms per meter squared (kg/m²) at screening~Exclusion Criteria:~* Have type 1 diabetes mellitus~* Have had chronic or acute pancreatitis any time prior to study entry~* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment~* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) enzyme level \>3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participants with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this trial only if there ALT level is ≤3.0 the ULN for the reference range~* Have an estimated glomerular filtration rate \<45 milliliters/minute/1.73 m² (or lower than the country specific threshold for using the protocol required dose of metformin per local label)~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2~* Have been taking any other diabetes medicines other than metformin during the last 3 months~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): 5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): 10 mg tirzepatide administered SC once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): 15 mg tirzepatide administered SC once a week.
- 1 mg Semaglutide (Type: ACTIVE_COMPARATOR): 1 mg semaglutide administered SC once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a Japanese, Korean, Taiwanese, or Chinese ethnic background of each country/region~* Patients aged ≥20 years on the date of informed consent~* Patients with histologically confirmed diagnosis of one of the following:~  * Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)~ * Angioimmunoblastic T-cell Lymphoma (AITL)~ * Anaplastic large cell lymphoma (ALCL), (ALK-positive/negative)~* Relapsed or refractory patients with a treatment history of at least one regimen with antitumor agents for the above disease~* Have at least 1 measurable lesion~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Patients with a life expectancy of at least 3 months as determined by the investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SP-02L (darinaparsin for injection) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1.Children 6 months to 72 months of age.~Exclusion Criteria:Children~1. Who had been hospitalized at the time of enrollment~2. Who had any serious reaction or hypersensitivity to any vaccine component, eggs, or chicken protein~3. Who had known impairment of the immune function~4. Who had fever interfering with normal daily activities at the time of enrollment~5. Who had received licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in the study~6. Concomitant participation in another clinical study~7. Who had surgery planned during the study period that in the investigator's opinion would have interfered with the study visits schedule.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 72 Months
- Healthy Volunteers: t

Study Arms:
- aTIV (6 to <72 months) (Type: ACTIVE_COMPARATOR): Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29
- Comparator TIV (6 to <72 months) (Type: ACTIVE_COMPARATOR): Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29
- TIV (6 to <72 months) (Type: ACTIVE_COMPARATOR): Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to \<36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 \& 29

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endocrine tumour in the intestine or pancreas and with locally advanced or metastatic disease~* No hormone related symptoms~* Well or moderately differentiated tumour confirmed by histology~* Tumour lesions which are measurable by a CT or MRI scan~Exclusion Criteria:~* Previously treated with a somatostatin analogue unless more than 6 months ago and given for no more than 15 days~* Treated within the last 6 months with interferon, chemoembolisation or chemotherapy or at any time with a radionuclide~* Had a previous cancer except basal cell carcinoma and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for 5 years~* Pregnant or lactating~* Females must use adequate contraception during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lanreotide (Autogel formulation) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years of age.~2. Histologically confirmed diagnosis of advanced solid or haematological malignancy not amenable to standard treatment.~3. Pharmacological treatment attempt justified~4. Preserved major organ functions, i.e:~   * B-Leukocyte count ≥ 3.0 x 109/L~  * B-Neutrophil count ≥ 1.5 x 109/L~  * B-Platelet count ≥ 75 x109/L~  * B-Haemoglobin ≥ 100 g/L (transfusions are allowed)~  * P-Total bilirubin level ≤ 1.5 times the upper institutional limit of the normal (i.e. reference) range~  * P-ASAT or P-ALAT ≤ 2.5 times upper institutional limit of the normal range, ≤5 times if liver metastases have been documented~  * P-Creatinine ≤ 1.5 times upper institutional limit of the normal range~5. Females of childbearing potential should use adequate contraception (oral or injectable contraceptives, hormone releasing intrauterine device) throughout the study period.~6. Signed written informed consent.~Exclusion Criteria:~1. Ongoing infection or other major recent or ongoing disease that, according to the investigator, poses an unacceptable risk to the patient~2. Known malignancy in CNS~3. Prior anti-tumour therapy within 4 weeks from enrolment (6 weeks for nitrosurea and MitC).~4. Pregnancy or lactation~5. Current participation in any other interventional clinical trial~6. Performance status \> ECOG 2 after optimization of analgesics~7. Life expectancy less than 3 months~8. Contraindications to the investigational product, e.g. known or suspected hypersensitivity.~9. Lack of suitability for participation in the trial, for any reason, as judged by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AXL1717 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AAT-App Outpatient Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Own an Android or iOS smartphone with an Australian mobile number.~* Be currently accessing outpatient treatment for alcohol problems. Participants with multiple drugs of concern are eligible as long as alcohol is one of the drugs of concern for the current episode of treatment.~* Have an Alcohol Use Disorders Identification Test (AUDIT) score of at least 8.~Exclusion Criteria:~* Any residential rehabilitation within the past 4 weeks.~* Any form of inpatient treatment (e.g. hospital or residential withdrawal treatment) within the past week.~* Scheduled to enter inpatient/residential treatment within the next month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active AAT-App (Type: EXPERIMENTAL): Participants will receive the active AAT-App.
- Minimal AAT-App (Type: SHAM_COMPARATOR): Participants will receive the minimal version of AAT-App.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4.~* For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC~* Progressed, or been intolerant to, at least one standard treatment regimen, except for participants in 1st line cohorts.~* ECOG performance status between 0 and 2~* At least 1 lesion with measurable disease at baseline~* Availability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy)~Exclusion Criteria:~* Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease~* Autoimmune disease~* Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent~* Uncontrolled CNS metastases~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Relatlimab (Type: EXPERIMENTAL): Relatlimab (BMS-986016) specified dose on specified days
- Relatlimab + Nivolumab (Type: EXPERIMENTAL): Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
- BMS-986213 (Type: EXPERIMENTAL): Relatlimab (BMS-986016) + Nivolumab (BMS-936558)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An RCT on Preventing Pressure Ulcers With Wheelchair Seat Cushions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 65 and older~* use wheelchair \> 6 hours per day~* no pressure ulcer on sitting surface~* Braden score of 18 or less~* combined activity and mobility Braden sub-score of 5 or less~Exclusion Criteria:~* Body Weight exceeds 250 lbs.~* Hip Width exceeds 20 inches~* does not meet all criteria of seating needs assessment~* current use of cushioning material or wheelchair better than study devices

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Segmented Foam Cushion (Type: ACTIVE_COMPARATOR): Receive seating assessment, wheelchair and seat cushion representing the standard of care in nursing homes
- Skin Protection Cushion (Type: EXPERIMENTAL): Receive seating assessment, wheelchair and cushion meeting CMS code for Skin Protection Wheelchair Cushion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum~* Stage IV~* Existence of two-dimensional measurable disease. The measurable disease should not have been irradiated.~* Absence or irradiated and stable central nervous system metastatic disease.~* Life expectancy of more than 3 months.~* Age ≥ 70 years.~* Performance status (WHO) ≤ 2.~* Adequate bone marrow function (Absolute neutrophil count \>1000/mm3, Platelet count \>100000/mm3, Hemoglobin \>9gr/mm3).~* Adequate liver (Bilirubin \<1.5 times upper limit of normal and SGOT/SGPT \<2 times upper limit of normal).~* Creatinine clearance (Cockcroft-Gault formula) \>30ml/min.~* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer.~* Presence of a reliable care giver.~* Informed consent.~Exclusion Criteria:~* Prior chemotherapy for metastatic disease.~* History of thromboembolic disease or myocardial infraction within the last 6 months.~* Peripheral neuropathy ≥ grade 2.~* Bowel obstruction or chronic diarrhea.~* Psychiatric illness or social situation that would preclude study compliance.~* Other concurrent uncontrolled illness.~* Other concurrent investigational agents.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XELOX/Avastin (Type: EXPERIMENTAL): Capecitabine Oxaliplatin Bevacizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Internet Based Adaptation of a Divorce Intervention Beginnings Program for Divorced Parents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents divorced, divorcing or separated~* Parents separated but never married~* One or more children aged 6 to 18~* Parents spoke English~* Parents spend at least 3 hours a week with children or have one overnight every other week with their children~* Parents have access to a computer with high speed internet access of a smart phone~Exclusion Criteria:~\* Parents who do not meet all of the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Online New Beginnings Program (eNBP) (Type: EXPERIMENTAL): The eNBP is a five-hour, asynchronous, fully web-based adaptation of the group NBP. Separate versions for fathers and mothers consist of the same didactic content and interactive exercises, with gender appropriate references, testimonials and video skills demonstrations. Units are highly interactive. Sessions began with a check-in in which parents responded to questions about use of the program skills and were provided with ways to address the challenges they experienced. The skill was then taught using modeling videos, interactive exercises, and testimonials from prior participants. The program then prompted parents to set times to use the skill, identify barriers to using it and select strategies to reduce these barriers. Parents were provided with tip sheets to address challenges in using the skill, downloadable sheets to record use of and competence in using the skill and a downloadable handbook that summarized what was covered in the unit.
- wait-list control condition (Type: NO_INTERVENTION): Parents in the waitlist-control condition were told that they would have access to the eNBP 12 weeks after they completed the pre-test. Twelve weeks after assignment to condition, parents and children were sent links to the posttest

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21+ years old~* Chronic ResMed ASV therapy patient~* Current ASV therapy for at least 4 weeks~* Able to understand fully the study information and participation requirements~* Provide signed informed consent~Exclusion Criteria:~* Acute cardiac decompensation~* Acute myocardial infarction within last 3 months~* Resuscitation within last 3 months~* Stroke with swallowing disorders or persistent hemiparesis~* Blood pressure test at end expiratory pressure (EEP) 10cmH2O not passed~* Untreated restless legs syndrome~* Alcohol or drug abuse~* Known cancer~* Pregnancy~* Conditions that could interfere with patients participating in and completing the protocol and/or the investigator deems their enrolment unsuitable

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Modified ASV (Type: EXPERIMENTAL): Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
- Conventional ASV (Type: ACTIVE_COMPARATOR): Conventional ASV This is the current (predicate) ASV algorithm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete